Adverum Biotechnologies, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating expenses:
Research and development
General and administrative
Impairment of goodwill and intangible assets
Total operating expenses

Operating loss
Other income, net
Net loss before income taxes
Income tax benefit
Net loss
Other comprehensive gain (loss):
Net unrealized gain on marketable securities
Transfer of currency translation adjustments balance to other income related to the liquidation of foreign subsidiaries
Foreign currency translation adjustment
Comprehensive loss

Net loss per share - basic and diluted (in dollars per share)
Weighted-average common shares outstanding-basic and diluted (in shares)
Net loss per share - basic (in USD per share)
Net loss per share - diluted (in USD per share)
Weighted-average common shares outstanding - basic (in shares)
Weighted-average common shares outstanding - diluted (in shares)

Comments